Clinical Research Directory
Browse clinical research sites, groups, and studies.
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
Sponsor: Nantes University Hospital
Summary
SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.
Official title: SEMAFOLLOW - Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity: Observational, National Cohort, Real-world Study in France
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
3000
Start Date
2026-06-01
Completion Date
2027-03-01
Last Updated
2026-02-27
Healthy Volunteers
No
Conditions
Interventions
SEMAFOLLOW questionnaire
If the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes
Locations (1)
Nantes university hospital
Nantes, France